From the NASDAQ listing notice on 16 Nov 2015, page 2 of the prospectus summary (my emphasis):
"Under our agreement with JCR, we are entitled to receive milestone payments on product regulatory approvals, escalating double digit royalties in the twenties and other payments at predefined thresholds of cumulative net sales"
You might also find some useful information about the aGVHD program that ran from 2008 to 2015 around page 111 of the prospectus. The results of the first 75 patients of this program were reported in 2013, but additional analysis of the first 160 patients is included in the prospectus.
From the NASDAQ listing notice on 16 Nov 2015, page 2 of the...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43508 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 34138 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |